FIGURE 7.

Efficacy of TPZ compound 11 in vivo. A, bound and unbound drug concentrations were measured by mass spectrometry in plasma, brain, and spleen at the indicated time point post-intravenous (tail vein) injection. B, measurement of whole-brain p935-LRRK2 levels from mice compared with total LRRK2. C, a significant reduction in Ser(P)-935 levels can be seen at the 5-min post-injection (*, p < 0.05) time point but not at subsequent time points. Immunoblots and calculated average values are representative of at least three mice per group. One-way analysis of variance with Tukey's post hoc corrections was used to calculate significance, and error bars represent mean ± S.E.